Navigation Links
Global Rheumatoid Arthritis Drug Market Outlook 2022
Date:3/16/2017

LONDON, March 16, 2017 /PRNewswire/ -- "Global Rheumatoid Arthritis Drug Market Outlook 2022" report gives comprehensive clinical and non-clinical insight on various trends associated with the rheumatoid arthritis drug market across the developed and developing market. Report helps to identify the basic classification and molecular mechanism of action of rheumatoid arthritis drugs available in the market. The top 5 leading DMARDs (Humira, Enbrel, Remicade, Simponi & Otezla) have dominated the overall anti-rheumatics market with total revenue surpassing more than US$ 25 Billion in 2016. These drugs will remain strong over the next 5 years, despite expected biosimilar competition.

Therapeutic advances have transformed the rheumatoid arthritis treatment paradigm over the last 20 years, from focusing on symptom management to now aiming for slowed disease progression and even disease remission. Disease-modifying biological medicines have ushered in a new age of treatment by targeting the cells involved in the progression of the disease.

These medicines have dramatically slowed or even reversed the negative physical effects associated with the disease and made clinical remission possible for patients with severe rheumatoid arthritis. The market of anti-rheumatics is growing at a constant speed globally. There are some driving factors which are accelerating the growth of anti-rheumatics market such as the increasing number of patients with rheumatoid arthritis, rise in research and development activities, increasing awareness among people about rheumatoid arthritis, and improved healthcare infrastructure in the region.

Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the molecular mechanisms involved. That approach changed with the introduction of biologic therapeutics at the end of the 20th century and by the recent development of small-molecule inhibitors of intracellular signal transduction pathways.

TNF-blocking biologic agents were introduced into the therapy of rheumatoid arthritis and other autoimmune and inflammatory diseases in the late 1990s. Further biologic agents targeting cytokine networks or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy. During the last few years, another wave of novel discoveries led to the development of a new class of small molecule anti-inflammatory compounds targeting intracellular signal transduction molecules, such as tyrosine kinases.

The most valuable development in treating Rheumatoid Arthritis will be biomarkers to help diagnose it early, identify those with more severe disease requiring more aggressive treatment, and indicate the most appropriate therapy for each person. Biomarkers may even help to decide the best time to step down therapy when a patient is in remission. There is a huge amount of research taking place, which reflects the excellent relationships between rheumatology health care professionals and people with Rheumatoid Arthritis.

"Global Rheumatoid Arthritis Drug Market Outlook 2022" report highlights:
- Classification & Molecular Mechanism of Rheumatoid Arthritis Drugs
- Synthetic DMARDs as Rheumatoid Arthritis Drug
- Biological Agents as Rheumatoid Arthritis Drug
- Global Market of Rheumatoid Arthritis Drug
- Global Tendencies in Use of Antirheumatics
- Global Rheumatoid Arthritis Drug Market Future Prospect
Download the full report: https://www.reportbuyer.com/product/4753869/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-rheumatoid-arthritis-drug-market-outlook-2022-300425031.html


'/>"/>
SOURCE ReportBuyer
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2019)... (PRWEB) , ... November 06, 2019 , ... Big Buzz ... as it charges forward into healthcare and medical technology. The agency - which primarily ... multiple awards, while team members spoke at prominent events nationwide. , In June, Big ...
(Date:11/6/2019)... ... 2019 , ... Enara Health , a technology-powered clinical ... behaviors that are associated with higher weight loss in individuals enrolled in a ... study, “Mobile Engagement Behaviors Associated With Sustained 15% Weight Loss,” provides real-world evidence ...
(Date:11/5/2019)... ... November 05, 2019 , ... Ida Culver House Broadview announced ... This will result in the layoff of 147 full- and part-time workers, and 53 ... transition will enable Ida Culver House Broadview to shift its care model to provide ...
Breaking Medicine Technology:
(Date:11/11/2019)... ... 11, 2019 , ... American Family Care , the ... expanding its long-term partnership with 919 Marketing , a national content marketing ... 200 locations across the country, American Family Care (AFC) is enlisting 919 Marketing’s ...
(Date:11/9/2019)... ... November 08, 2019 , ... The Women’s Dermatologic Society (WDS) ... health concerns. The WDS Board of Directors appointed Molly Hinshaw, MD to fill the ... current March 2019-March 2020 term and will be presented to the membership as the ...
(Date:11/7/2019)... ... 06, 2019 , ... Atlantic Ultraviolet Corporation makes it their business to fight ... shot. Since the flu season starts in October until March, Atlantic Ultraviolet makes it ... can simply sign-up and get their shot. , Ann Wysocki, COO of Atlantic Ultraviolet ...
(Date:11/7/2019)... ... November 07, 2019 , ... Understanding UDI in EU Device ... https://www.fdanews.com/understandudi , Are EU device and IV diagnostics sales in jeopardy? , ... regulations —UDI — is ahead, and many device and diagnostics makers simply aren’t prepared. ...
(Date:11/6/2019)... ... November 06, 2019 , ... ... plan market, announced today that 94% of the health insurance plans receiving the ... Medicaid health insurance plans, use SPH solutions according to reports recently released ...
Breaking Medicine News(10 mins):